Prevent Biometrics® Announces Commercial Launch of Head Impact Monitor System, Bringing Advanced Real-Time Monitoring of Concussion Impacts to Sports
Prevent Biometrics, the Cleveland Clinic spinoff that created the first and only head impact monitoring technology to accurately detect potential concussion-causing impacts in real time, announces its newest innovation at the Consumer Electronics Show today: the Gen 1.2 Head Impact Monitor System, bringing advanced, never-before-available head impact analytic capabilities to schools, associations, teams and coaches.
Centerline Biomedical Completes Fifth Preclinical Study
As Centerline Biomedical, Inc. prepares to meet with investors, strategic partners and companies in the healthcare industry during the JP Morgan Healthcare Conference, it successfully completed a fifth preclinical study at Cleveland Clinic facilities evaluating its surgical navigation system, IOPS, the Intra-Operative Positioning System. This study was the most noteworthy Centerline study to date, demonstrating ability to track sensorized IOPS instruments precisely and efficiently, with enhanced 3-D visualization, without frequent exposure to cancer-causing ionizing radiation associated with current standard of care. Endovascular surgeries i.e. those which repair arteries using stents rely on X-ray fluoroscopy, which provides limited two-dimensional visualization, leading to long procedure times while exposing surgeons and patients to damaging radiation. IOPS, originally developed at Cleveland Clinic, uses a 3-D model of a patient's vascular system to track instruments precisely without ionizing radiation, with the goal of reducing procedure times, complication rates, and overall costs. The mathematical algorithms used to generate the 3-D model are currently being used to revolutionize minimally invasive surgery, with future applications in surgical training and clinical decision support.
Quest Diagnostics finalizes purchase of Cleveland Clinic spinoff Cleveland HeartLab
Quest Diagnostics today finalized its acquisition of Cleveland Clinic spinoff Cleveland HeartLab.
NaviGate Cardiac Structures, Inc. Reports “Exceptional” Six-Week Results for Two Implantations of Its GATE™ Atrioventricular Valved Stent (AVS) to Correct Severe Tricuspid Regurgitation Patients
NaviGate Cardiac Structures Inc. (“NCSI”) announced today “exceptional results” for implantation of its GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) at six-week follow-up in two nonagenarian patients presenting with severe tricuspid valve insufficiency.
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
Genomic Health, Inc. (Nasdaq : GHDX ), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics' IsoPSA™ reagents and technology.
Quest Diagnostics to acquire Cleveland Clinic spinoff Cleveland HeartLab
Quest Diagnostics signed a deal with Cleveland Clinic spinoff Cleveland HeartLab to acquire the company before the end of the year.
ClearFlow, Inc. Announces Positive US Clinical Trial Results
ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY.
Exclusive: Woman Can Move Again After a Breakthrough Stroke Treatment
The first person to receive deep brain stimulation (DBS) for stroke recovery is performing far better than her doctors anticipated.
ClearFlow, Inc. Receives FDA Clearance for FlowGlide Technology for Cardiac Surgery Patients
ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System.
Cleveland Clinic-led Study Finds That New Blood Test is More Accurate in Predicting Overall Risk of Prostate Cancer than Standard Prostate-Specific Antigen (PSA)
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.